Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Xiaorong Liang
Phase Ia Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) in Patients With Recurrent Advanced Solid Tumors
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions
Journal of Pharmaceutical Sciences
Pharmaceutical Science
Related publications
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Indoleamine 2,3-Dioxygenase 1 (IDO1)
Science-Business eXchange
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Refractory, Locally Advanced or Metastatic Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3 Dioxygenase 1
Biophysical Journal
Biophysics
A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
Chemical and Pharmaceutical Bulletin
Medicine
Drug Discovery
Chemistry
A Phase I Study of NLG919 for Adult Patients With Recurrent Advanced Solid Tumors
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Advances in Indoleamine 2,3-Dioxygenase 1 Medicinal Chemistry
MedChemComm
Organic Chemistry
Molecular Medicine
Pharmacology
Biochemistry
Pharmaceutical Science
Drug Discovery
A Phase 1 Study of Alpelisib (BYL719), an Α- Specific PI3K Inhibitor, in Japanese Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Oncotarget
Oncology
